Global Molecular Imaging Market 2021-2026 - Supportive Government Regulations for Healthcare will be a Tailwind for Growth
DUBLIN, July 29, 2021 /PRNewswire/ -- The "Molecular Imaging Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
The global molecular imaging market is evaluated at US$4.199 billion for the year 2019 growing at a CAGR of 5.68% reaching the market size of US$6.183 billion by the year 2026.
In terms of diagnosis, molecular imaging can provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery identify disease in its earliest stages and determine the exact location of a tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests.
As a tool for evaluating and managing the care of patients, molecular imaging studies help physicians; determine the extent or severity of the disease, including whether it has spread elsewhere in the body, select the most effective therapy based on the unique biologic characteristics of the patient and the molecular properties of a tumor or other disease, determine a patient's response to specific drugs, accurately assess the effectiveness of a treatment regimen, adapt treatment plans quickly in response to changes in cellular activity, assess disease progression, identify recurrence of disease and help manage ongoing care.
Rising technological advancements in the healthcare sector at a global level will drive the market during the forecast period.
The growth of the molecular imaging market is fuelled by the increasing technological advancements taking place in the sector at an exponential rate. The technological advancements in the field of imaging have always been challenging to practitioners in how best to optimize their inpatient care.
Over recent years, scientists, researchers, and technologists have been able to bring systems in clinical practice, in which two or even more two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT. Furthermore, the increased use of AI-enabled diagnostic equipment for rapid diagnosis and predictive analysis is developed in several countries across the world.
Under this program, the DOE/NNSA makes LEU (Low Enriched Uranium) available through lease contracts for the irradiation and production of Mo99 for medical uses. The AMIPA not only promotes the domestic production of Mo-99 but also aims to replace the role of HEU (High Enriched Uranium) in the production of medical radioactive isotopes.
Moreover, Canada is one of the largest producers of Technetium-99m. With the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. It is also combined with a variety of biologically active molecules to perform non-invasive, real-time imaging of the human body.
The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered along with the recent deals and investments of these important players in the market.
Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/r/d4jenx
For E.S.T Office Hours Call +1-917-300-0470
U.S. Fax: 646-607-1904
View original content:https://www.prnewswire.com/news-releases/global-molecular-imaging-market-2021-2026---supportive-government-regulations-for-healthcare-will-be-a-tailwind-for-growth-301344165.html
SOURCE Research and Markets
Asset Management â€“ Keeping Remote Devices Connected
Ease Interoperability in Smart Cities - How Standards Can Prevent Vendor-lock-in
7 Elements of a Successful Cannabis VAR